S
Stéphane Paul
Researcher at French Institute of Health and Medical Research
Publications - 238
Citations - 5729
Stéphane Paul is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Medicine & Infliximab. The author has an hindex of 36, co-authored 199 publications receiving 4592 citations. Previous affiliations of Stéphane Paul include University of Veterinary Medicine Hanover & Jean Monnet University.
Papers
More filters
Journal ArticleDOI
Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
Xavier Roblin,Hubert Marotte,Melanie Rinaudo,Emilie Del Tedesco,Amélie Moreau,Jean-Marc Phelip,Christian Genin,Laurent Peyrin Biroulet,Stéphane Paul +8 more
TL;DR: Trough levels of adalimumab are significantly higher in IBD patients who are in clinical remission and in those with mucosal healing, and Detection of antibodies against adAlimumab predicts a lack of mucosal Healing.
Journal ArticleDOI
Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
Stéphane Paul,Emilie Del Tedesco,Hubert Marotte,Melanie Rinaudo-gaujous,Amélie Moreau,Jean-Marc Phelip,Christian Genin,Laurent Peyrin-Biroulet,Xavier Roblin +8 more
TL;DR: Therapeutic drug monitoring of IFX strongly predicts the likelihood of achieving mucosal healing in inflammatory bowel diseases following IFX dose intensification in both CD and UC.
Journal ArticleDOI
Gene-based vaccines and immunotherapeutics
Margaret A. Liu,Bruce Acres,Jean-Marc Balloul,Nadine Bizouarne,Stéphane Paul,Philippe Slos,Patrick Squiban +6 more
TL;DR: Examples of in vivo prophylaxis and immunotherapy, based on different types of immune responses (humoral and cellular), in a variety of disease models and under evaluation in early phase human clinical trials are presented.
Journal ArticleDOI
New insights in mucosal vaccine development
TL;DR: This review focuses on contemporary developments of mucosal vaccination approaches using different routes of administration to induce broad potent protective immunity by specific neutralizing antibodies at mucosal surfaces and by induction of cellular immunity.
Journal ArticleDOI
Development of an Algorithm Incorporating Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases
Xavier Roblin,Melanie Rinaudo,E. Del Tedesco,Jean-Marc Phelip,Christian Genin,Laurent Peyrin-Biroulet,Stéphane Paul +6 more
TL;DR: The presence of low ADA trough levels without AAA is strongly predictive of clinical response in 67% of cases after ADA optimization, and switching to IFX should be considered.